The Mortgage Bankers Association (MBA) released its weekly report on mortgage applications Wednesday morning, noting a decrease of 0.5% in the group’s seasonally adjusted composite index for the week ending June 29. Mortgage loan rate movements were mixed last week.
Let Clients Figure the Retirement Funding Catastrophe Out for Themselves
Consultants at Milliman Inc. have come up with hard numbers that may back up an allegation patients and providers have been making for years: that many health insurers have skimpy mental health and addiction treatment....More>>>
Uranium has been back in the news lately, not only due to its relationship with geopolitical maneuvering concerning nuclear weapons, but also as a necessary commodity in the global quest for clean, renewable energy.
The United States is the world’s largest producer of nuclear power, accounting for more than 30% of worldwide nuclear generation of electricity. While....More>>>
Valeritas (NASDAQ: VLRX) is one of 106 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its competitors? We will compare Valeritas to similar businesses based on the strength of its analyst recommendations, profitability, institutional ownership, earnings, valuation, dividends and risk.
Wynn Resorts (NASDAQ:WYNN) continues to trend higher, even after steady growth over the last year. The gaming company still warrants a buy as underlying fundamentals remain strong. As the Macau region further strengthens, Wynns presence there should lead to revenue growth. A stronger U.S. consumer is also aiding the companys domestic operations. Moreover, its valuation multiples signal the company....More>>>
Even with interest rates edging up lately, it still isnt easy to pocket much income from traditional stocks and bonds. But you may be overlooking preferred stocks, hybrid investments that offer a bit of both worlds.
SEE ALSO: Kiplinger’s Interest Rate Forecast
For income seekers, preferreds offer great deals. Yields average 6.1%, well above the 2.3% payout of the Barclays....More>>>
Related HTZ Must Watch Stocks For May 9, 2016 Earnings Scheduled For May 9, 2016 Notable earnings after Monday's close (Seeking Alpha) Related Earnings Scheduled For May 10, 2016 Stifel Remains Bullish On Electronic Arts Despite Expectation For Light FY17 Outlook Investing....More>>>
February17, 2017: Markets opened lower Friday following a mixed Thursday close. There was little noteworthy economic news and the Monday President’s Day holiday may have encouraged some traders to get a head start on the weekend. The energy and materials sectors were the biggest losers offset by gains in counter-cyclicals. WTI crude oil for March delivery settled at $53.40a barrel, up less....More>>>
SOFIA, Bulgaria The European Union has called on U.S. President Donald Trump's administration to stop threating it with tariffs on steel and aluminum, saying Thursday it is prepared to discuss trade but not at gun-point.
In March, Trump slapped tariffs of 25% on steel imports and 10% on impo
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one high-profile Wall Street pick and putting it under the microscope...
Editor's note: Seeking Alpha is proud to welcome Michael McGrath as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more 禄
If you're not familiar with how Social Security works, you might assume that there's a single age at which eligible recipients have to file for benefits. Not so. You actually get an eight-year window to claim benefits that begins at age 62 and carries through until age 70. (Technically, you're no
The biopharma and drug supply chain sectors outperformed the market last week, even as Trump administration officials pressed the president's blueprint to lower drug prices, with tough rhetoric for drugmakers and public shaming of pharmaceutical firms for supposedly blocking competition.